http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The Adequate Resection Margin of Hepatocellular Carcinoma According to the Tumor Microenvironment
( Sung Hoon Kim ),( Yun Tae Kim ),( Joon Hyung Sohn ),( Mee-yon Cho ),( Moon Young Kim ),( Soon Koo Baik ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: There is no consensus on the safe resection margin in patients with hepatocellular carcinoma (HCC). We investigated the change of tumor microenvironment according to the resection margin. Methods: We prospectively collected the specimen of 60 patients with HCC. We selected three portions of specimens as follows: tumor, 1cm and 2cm margin normal tissue. We investigated the expression status of tumor microenvironment genes. We compared the expression status according to recurrence, HCC gross type and positron emission tomography (PET) positivity. We divided the patients into two groupsas follows: group 1 included expanding and vaguely nodular types whereas group 2 included nodular with perinodular extension, multinodular confluent and infiltrative types. Results: Group 2 had a higher prevalence of PET positive [6 (37.5%) vs 10 (62.5%)] and recurrence [5 (16.7%) vs 17 (56.7%)]. However, in cases with more than 1cm resection margin, there was no difference of recurrence rate [9 (75%), P=0.017 vs 8 (44.4%), P=0.06]. Beta-catenin was significantly decreased and E-cadherin was significantly increased according to the resection margin in group 1. Group 2 and PET positive patients showed Group 1 did not show any significant change of beta-catenin and E-cadherin until 2cm resection margin. Conclusions: Our data suggest that patients with HCC of expanding and vaguely nodular gross types may safely undergo surgical resection with a narrow resection margin and patients with HCC of nodular with perinodular extension, multinodular confluent and infiltrative gross type must undergo surgical resection with more than 2cm resection margin because of tumor microenvironment condition.
Sang-Cheol Cho,Eun-Sun Jin,Sang Yong Om,Ki Won Hwang,최형오,Ki-Hun Kim,Sung-Hwan Kim,Kyoung-Min Park,Jun Kim,Ki-Joon Choi,You-Ho Kim,Gi-Byoung Nam 대한심장학회 2020 Korean Circulation Journal Vol.50 No.11
Background and Objectives: Pacemaker (PM) implantation is a well-accepted treatment option for patients with paroxysmal atrial fibrillation (AF) and related tachycardia-bradycardia syndrome (TBS). Data on the long-term clinical outcomes after radiofrequency catheter ablation (RFCA) or PM implantation are sparse. Methods: The medical records of 217 patients with TBS were retrospectively assessed. Outcomes in patients who underwent RFCA (n=108, 49.8%) were compared to those with PM implantation (n=109, 50.2%). The clinical outcomes were sinus rhythm maintenance, conversion to persistent AF, additional procedure or crossover, and the composite of cardiovascular hospitalization and death. Results: During the follow-up period (mean 3.5±2.0 years), the RFCA group, compared to the PM group, showed better sinus rhythm maintenance (adjusted hazard ratio [aHR], 0.27; 95% confidence interval [CI], 0.15–0.46; p=0.002) and less progression to persistent AF (aHR, 0.20; 95% CI, 0.06–0.63; p=0.006). Additional procedure or crossover did not differ significantly between the groups (aHR, 2.07; 95% CI, 0.71–6.06; p=0.185 and aHR, 0.69; 95% CI, 10.8–2.67; p=0.590, respectively). Most RFCA patients (92.6%) did not require pacemaker implantation during long term follow-up period (>3.5 years). The composite endpoint of cardiovascular rehospitalization and death was not significantly different between the groups (aHR, 0.92; 95% CI, 0.50–1.66; p=0.769). Conclusions: RFCA is an effective alternative to PM implantation in patients with TBS. In these patients, successful RF ablation of AF is related to a higher rate of sinus rhythm maintenance compared to PM implantation, and the composite outcome of cardiovascular rehospitalization and death is similar.
( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( Hee Yeon Kim ),( Chang Wook Kim ),( Chan Ran You ),( Sang Wook Choi ),( Se Hyun Cho ),( Joon-Yeol Han ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: We have evaluated the efficacy and safety of the sofosbuvir (SOF) and weight-based ribavirin (RBV) therapy in genotype 2 hepatitis C virus (HCV) infected Korean patients in real clinical settings. Methods: A total of 323 patients who received SOF plus RBV between May 2016 and February 2017 at the liver unit of the Catholic University of Korea were consecutively recruited and analyzed. Patients with chronic hepatitis and cirrhosis underwent 12 weeks and 16 weeks of antiviral therapy, respectively. The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12). Results: The mean age was 61.6±11.8 years and 36% of the patients were male. 238 (73.7%) patients had chronic hepatitis, 78 (24.1%) compensated cirrhosis, and 7 (2.2%) decompensated cirrhosis. 17 (5.3%) patients had a history of hepatocellular carcinoma treatment. 52 (16.1%) patients were treatment experienced (7 non-responders, 33 prior relapse, and 12 intolerable to interferon based treatment). 95.1% (293/308) of the patients achieved undetectable HCV RNA at week 4, 99.6% (255/256) end of treatment response and 96.6% (141/146) SVR12. No difference was observed according to age, previous treatment experience, viral load and cirrhosis (P>0.05). Overall, the SOF plus RBV regimen was well-tolerated but 4 patient discontinued treatment due to possible drug-related side effects. The most frequently observed adverse event was anemia and 15.9% (47/296), 5.4% (16/296) of the patients experienced grade 2 and grade 3 anemia, respectively. The doses of RBV were reduced to median 825mg and 577mg daily in grade 2 and 3 anemia groups, respectively but the SVR12 were 100% in both groups. Conclusions: Sofosbuvir and ribavirin regimen resulted in a high SVR rate and was tolerable in genotype 2 HCV infected Korean patients in real clinical practice.
( Sung Won Chung ),( Young Youn Cho ),( Jeong-hoon Lee ),( Young Chang ),( Joon Yeul Nam ),( Yun Bin Lee ),( Eun Ju Cho ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-hwan Yoon ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: A number of Asian-Pacific centers perform transarterial chemoembolization (TACE) as the first treatment for advanced hepatocellular carcinoma (HCC), although sorafenib is the standard first-line treatment. In this study, we aimed to compare the overall survival (OS) according to initial treatment (TACE vs sorafenib) among patients experiencing sorafenib treatment in advanced HCC. Methods: We included 200 consecutive patients treated with sorafenib for >4 weeks with or without TACE for advanced HCC at a single tertiary hospital in Korea. The primary endpoint was OS and secondary endpoints included time to progression (TTP) and objective response rate (ORR) and disease control rate (DCR). The risk was compared between groups using a Cox proportional hazards model and inverse probability weighting (IPW) analysis. Results: Eighty-seven patients were initially treated with sorafenib (the sorafenib-first group: 54 treated with sorafenib only and 33 treated with sorafenib followed by TACE) and 113 patients were treated with TACE followed by sorafenib therapy (the TACE-first group). Twenty-eight patients (14%) were Child-Turcotte-Pugh class B and there was no significant difference in baseline characteristics between two groups except sorafenib-first group had more ascites (17.2% vs 7.1%, P=0.04) and prolonged prothrombin time (1.2±0.1 vs 1.1±0.1, P=0.02). The TACE-first group showed significantly longer OS than the sorafenib-first group (hazard ratio [HR]=0.62, 95% confidence interval [CI]=0.45-0.85, log-rank P=0.004). Median OS was 11.6 months in the TACE-first group and 6.9 months in the sorafenib-first group. The TACE-first group had significantly longer OS in multivariable analysis (adjusted HR=0.58; 95% CI=0.41-0.80, P=0.001 and IPW analysis (HR=0.63, 95% CI=0.44-0.91, P=0.01). There was no significant difference in TTP between two groups (HR=0.89, 95% CI=0.62-1.28, P=0.53). ORR was 6.9% in the sorafenib-first group and 10.6% in the TACE-first group (P=0.27 by chi-square test). DCR was 56.3% in the sorafenib-first group and 73.5% in the TACE-first group (P=0.01 by chi-square test). Conclusions: For patients with advanced HCC, second-line sorafenib treatment following TACE has significantly longer OS than first-line sorafenib treatment. An initial aggressive intrahepatic tumor control with loco-regional therapies followed by sorafenib treatment may be a potent strategy for advanced HCC.
Properties of Indium Doped Zinc Oxide Thin Films Deposited by RF Magnetron Sputtering
Joon Ho Bang,Se Hun Park,Sang Hyun Cho,Pung Keun Song 한국표면공학회 2010 한국표면공학회지 Vol.43 No.4
Indium doped zinc oxide films (ZIO) were deposited on non-alkali glass substrates by radio frequency (RF) magnetron sputtering at room temperature. The structural, electrical and optical properties of the ZIO films were investigated as a function of their In₂O₃ content (3.33-15.22 wt%). The ZIO films deposited with an In₂O₃ content of 9.54 wt% showed a relatively low resistivity of 9.13×10<SUP>?4</SUP> Ω㎝ and a highly c-axis preferred orientation. The grain size and FWHM were mainly affected by the In₂O₃ content. The crystallinity and resistivity were enhanced with increasing grain size. The average transmittance of the ZIO films was over 85% in the visible region and their band gap varied from 3.22 to 3.66 eV depending on their doping ratio.
( Sang Jin Lee ),( Yoon Chul Jung ),( Dong Ok Jeon ),( Hyo Jin Cho ),( Sung Gyu Im ),( Sun Kyung Jang ),( Ho Joon Kang ),( Mi Jung Kim ),( Jang Han Lee ) 대한신장학회 2013 Kidney Research and Clinical Practice Vol.32 No.4
Background: Diabetic patients are predisposed to foot infections because of vascular insufficiency and peripheral neuropathy. Diabetic foot infection is a common cause of mortality and lower extremity amputations (LEAs) in patients with chronic kidney disease (CKD). We evaluated the risk factors for mortality and LEAs in patients with stage 3 CKD or higher with diabetic foot infections. Methods: We retrospectively evaluated a cohort of 105 CKD patients with diabetic foot infections between July 1998 and December 2011. We reviewed their demographic characteristics and laboratory parameters to evaluate the risk factors for mortality and amputations at 24 weeks after diagnosis of a diabetic foot infection. Results: The mortality of the 105 enrolled CKD patients was 21% at 24 weeks after the diagnosis of a diabetic foot infection. Cox proportional regression analyses revealed that age 60 years or older [odds ratio (OR) 3.03, 95% confidence interval (CI) = 1.02-9.02, P = 0.047] and initial serum C-reactive protein (CRP) level ≥ 3 mg/ dL (OR 3.97, 95% CI = 1.17-13.43, P = 0.027) were independent risk factors for mortality at 24 weeks. Twenty-four patients (23%) underwent LEAs. On Cox proportional regression analyses, peripheral vascular disease (OR¼4.49, 95% CI¼1.98-10.17, P¼0.01) and cerebrovascular accident (OR 2.42, 95% CI¼1.09-5.39, P¼0.03) were independently associated with LEAs. Conclusion: This study showed that age and serum CRP level, were independent risk factors for mortality at 24 weeks in patients with stage 3-5 CKD with diabetic foot infections. Peripheral vascular disease and cerebrovascular accident were significantly associated with LEAs.
Sung-Soo Park,Hee-Je Kim,Tong Yoon Kim,Joon yeop Lee,Jong Hyuk Lee,Gi June Min,Silvia Park,Jae-Ho Yoon,Sung-Eun Lee,Byung-Sik Cho,Ki-Seong Eom,Yoo-Jin Kim,Seok Lee,Dong-Wook Kim 대한혈액학회 2021 Blood Research Vol.56 No.3
Background Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative treatment option for acute leukemia. We aimed to identify the comorbidity factors affecting survival outcomes after alloSCT and develop a new comorbidity index tool for predicting overall survival (OS). Methods A Korean nationwide cohort of 3,809 adults with acute leukemia treated with alloSCT between January 2002 and December 2018 was analyzed as the development cohort. A retrospective cohort comprising 313 consecutive adults with acute leukemia who underwent alloSCT between January 2019 and April 2020 was analyzed as the validation cohort. Results In the development cohort, advanced age, male sex, and comorbidities such as previous non-hematologic malignancy, hypertension, and coronary or cerebral vascular disease were significantly related to poor OS. Subsequently, a new comorbidity scoring system was developed, and risk groups were created, which included the low-risk (score ≤0.17), intermediate-risk (0.17< score ≤0.4), high-risk (0.4< score ≤0.55), and very high-risk (score >0.55) groups. The 1-year OS rates were discriminatively estimated at 73.5%, 66.2%, 61.9%, and 50.9% in the low-risk, intermediate-risk, high-risk, and very high-risk groups in the development cohort, respectively (P<0.001). The developed scoring system yielded discriminatively different 1-year OS rates and 1-year incidence of non-relapse mortality according to the risk group (P=0.085 and P=0.018, respectively). Furthermore, the developed model showed an acceptable performance for predicting 1-year non-relapse mortality with an area under the curve of 0.715. Conclusion The newly developed predictive scoring system could be a simple and reliable tool helping clinicians to assess risk of alloSCT in adults with acute leukemia.
Modified 'Y-Configured Stents with Waffle Cone Technique' for Broad Neck Basilar Top Aneurysm
Cho, Jun-Sung,Kim, Young-Joon The Korean Neurosurgical Society 2011 Journal of Korean neurosurgical society Vol.50 No.6
Stent assisted coiling on intracranial broad neck aneurysm has been considered as an effective technique and has made the complex aneurysms amenable to coiling. However, stent navigation and application themselves often have the problems especially when the parent vessel angle (entrance between afferent and efferent vessel) is over 90 degrees. We report here a case of a ruptured broad neck basilar top aneurysm that was successfully coiled using two self-expandable stents (Enterprise and Neuroform) placed in a fashion of modified Y-configured stents with waffle cone technique.